Fulvestrant in heavily pretreated metastatic breast cancer: Is it still effective as a very advanced line of treatment?

Israel Medical Association Journal

Volumn 10, Issue 5, 2008, Pages 339-343

  Safra, Tamar ^a   Greenberg, Julia ^a   Ron, Ilan G ^a   Ben Yosef, Rami ^a   Inbar, Moshe ^a   Sarid, David ^a   Yaal Hahoshen, Neora ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fulvestrant; Hormone receptor positive tumors; Pretreated metastatic breast cancer

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 48149100954     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wakeling AE, Dukes M, Bowler J. A potent pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873.
2. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Relat Cancer 2000;7:17-28.
3. Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004; 10(Suppl):362s-367s.
4. Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Molec Biol 2005;95:113-119.
5. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors. J Clin Oncol 2000;18:2234-2244.
6. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
7. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
8. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast cancer in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
9. Ingle JN, Rowland KM, Suman VJ. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group [Abstract]. Breast Cancer Res Treat 2004; 88(Suppl 1):S38. Abstract 409.
10. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003;9(Suppl):460s-467s.
11. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial [Review]. J Clin Oncol 2002;15:3386-3395.
12. Robertson JF, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92:169-174.